Close Menu

Prostate Cancer

News and reporting on prostate cancer.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.

The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.

Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.

The firm claims that its liquid biopsy platform can identify mutations in patient samples at femtogram-level concentrations.

The company recently launched Prompt Prostate Genetic Score, a lab-developed test to track a man's genetic predisposition to prostate cancer.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.

The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.

Through the deal, Helomics aims to build a predictive model of prostate cancer drug response based on a combination of genomic and spectroscopy data.

Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.

The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.